ESMO 2023

ESMO 2023
October 20-24, 2023
Madrid Spain

European Society for Medical Oncology.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (4)

    Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase 2 TROPiCS-03 basket trial

    • Author(s): Dowlati, A
    • trodelvy
    • Oncology
    • Oral

    Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase 2 TROPiCS-03 basket trial

    • Author(s): Michel, L
    • trodelvy
    • Oncology
    • Oral

    Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)

    • Author(s): Kalinsky, K
    • trodelvy
    • Oncology
    • Poster

    Efficacy and safety analyses by prior lines of chemotherapy from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

    • Author(s): Cortes, J
    • trodelvy
    • Oncology
    • Poster